AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 108 filers reported holding AVROBIO INC in Q4 2020. The put-call ratio across all filers is 2.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $179,079,000 | -37.2% | 32,093 | 0.0% | 0.00% | – |
| Q2 2021 | $285,307,000 | -91.8% | 32,093 | -88.2% | 0.00% | -100.0% |
| Q1 2021 | $3,461,617,000 | -8.6% | 272,783 | +0.4% | 0.00% | 0.0% |
| Q4 2020 | $3,789,087,000 | -1.9% | 271,814 | -8.4% | 0.00% | 0.0% |
| Q3 2020 | $3,863,073,000 | -23.9% | 296,703 | +2.0% | 0.00% | -33.3% |
| Q2 2020 | $5,077,653,000 | +18.7% | 290,983 | +5.9% | 0.00% | 0.0% |
| Q1 2020 | $4,277,132,000 | +24.5% | 274,880 | +61.1% | 0.00% | +50.0% |
| Q4 2019 | $3,434,943,000 | +65.2% | 170,638 | +15.9% | 0.00% | +100.0% |
| Q3 2019 | $2,079,495,000 | -13.2% | 147,273 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $2,394,659,000 | -28.0% | 147,273 | -2.4% | 0.00% | 0.0% |
| Q1 2019 | $3,325,537,000 | +30.1% | 150,818 | -1.8% | 0.00% | 0.0% |
| Q4 2018 | $2,556,341,000 | -59.8% | 153,534 | +25.4% | 0.00% | -60.0% |
| Q3 2018 | $6,352,311,000 | +90.1% | 122,466 | +4.7% | 0.01% | +66.7% |
| Q2 2018 | $3,341,520,000 | – | 117,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |